AOD-9604 and Tesamorelin are supplied strictly as laboratory research materials. They are not approved, intended or authorised for human consumption or any therapeutic use in this context. This article is written for qualified researchers and is not medical advice.
Same target, opposite routes
Both of these peptides sit inside the growth-hormone story, and both are studied for their effect on fat — yet they attack the problem from opposite ends of the axis. AOD-9604 is a piece of growth hormone itself: a synthetic fragment of the molecule's C-terminus, built to carry the fat-mobilising signal and nothing else. Tesamorelin never touches the fat directly; it acts one step upstream, on the pituitary, telling the body to secrete more of its own GH. Direct GH fragment versus the GHRH — the upstream — approach. Read the table down and that single distinction explains almost every other difference between them.
| AOD-9604 | Tesamorelin | |
|---|---|---|
| Class / peptide type | Lipolytic hGH C-terminal fragment (176-191) | Stabilised GHRH (hGRF 1-44) analogue |
| Primary mechanism | Direct lipolysis in adipocytes; no rise in GH/IGF-1 | Stimulates the pituitary to release endogenous GH, raising IGF-1 |
| Structure / MW | 16 amino acids · ~1815 Da | 44 amino acids · ~5136 Da |
| Approx. half-life | ~30 minutes | ~25–40 minutes |
| Main research focus | Adipose lipolysis; parallel cartilage/joint line | Visceral adipose tissue reduction |
| Effect on IGF-1 | None reported | Raises IGF-1 (upper-normal range) |
| Regulatory status | US GRAS (food ingredient); unapproved as a medicine | FDA-approved (Egrifta, 2010) |
AOD-9604: the isolated GH fragment
AOD-9604 (originally coded "Anti-Obesity Drug 9604") is a synthetic 16-amino-acid peptide modelled on the C-terminal region of human growth hormone — residues 176-191 — with an added N-terminal tyrosine to stabilise the molecule. That C-terminal region is where hGH's lipolytic activity lives, and the peptide was engineered to isolate exactly that: it retains the fat-mobilising signal while deliberately dropping the residues responsible for the growth-promoting and IGF-1-elevating effects of full-length GH.
Mechanistically, preclinical work points to upregulation of β3-adrenergic signalling in adipose tissue, driving the cAMP/PKA cascade that activates hormone-sensitive lipase and triggers triglyceride hydrolysis — the same downstream lever engaged by exercise and adrenergic stimulants. The defining feature in the research literature is what does not happen: dosing does not elevate plasma IGF-1 or stimulate cartilage growth, separating the metabolic axis from the anabolic one. A 2007 Phase 2b study in overweight and obese adults reported a modest, dose-dependent weight-reduction signal with favourable tolerability, though the effect size was not large enough to carry a primary clinical programme. A separate line of research has explored C-terminal hGH fragments for chondroprotective activity in osteoarthritis models. The full mechanism sits on our AOD-9604 knowledgebase page; researchers sourcing material can buy AOD-9604 UK at ≥99% purity with a COA.
Tesamorelin: the upstream GHRH analogue
Tesamorelin (code TH9507) takes the opposite route. It is a synthetic 44-amino-acid analogue of human growth-hormone-releasing hormone (GHRH/hGRF), modified at the N-terminus with a trans-3-hexenoyl group that confers resistance to dipeptidyl peptidase-4 (DPP-4) degradation. Rather than acting on fat directly, it binds the GHRH receptor on anterior-pituitary somatotrophs and drives pulsatile release of the body's own growth hormone. Because the stimulus is endogenous, the physiologic feedback loops — pulse architecture, somatostatin suppression, IGF-1 negative feedback — stay intact, a meaningful research distinction from administering recombinant GH.
The DPP-4-resistant backbone is the key piece of engineering: native GHRH is cleaved within minutes, whereas Tesamorelin's modified structure resists that cleavage and sustains a physiologic-pattern GH pulse. It is the only GHRH analogue to have reached FDA approval as a medicine — marketed as Egrifta for HIV-associated lipodystrophy — where clinical research documented preferential reduction of visceral adipose tissue alongside lipid and insulin-resistance improvements, with IGF-1 rising into the upper end of the normal range. Its evidence base is the deepest of any GHRH analogue. In stack research it is most often paired with the selective GHRP ipamorelin, which engages a non-overlapping ghrelin-receptor pathway. See the Tesamorelin knowledgebase page for the detail, or buy Tesamorelin UK as research-grade material.
What the differences mean in a research context
The cleanest way to hold these two apart is by what they touch. AOD-9604 acts at the fat cell: it is a fragment of GH that carries the lipolytic message directly, without recruiting the wider hormonal cascade. Its signature in the data is the absence of an IGF-1 rise — the whole point of isolating the fragment was to leave the growth and anabolic effects behind. That makes it a tool for studying lipolysis in near-isolation from the rest of the GH axis.
Tesamorelin acts at the pituitary: it raises the body's own GH and, with it, IGF-1. Where AOD-9604 tries to sidestep the axis, Tesamorelin deliberately drives it — which is why it is the compound of interest when the experimental aim is GH/IGF-1 modulation itself, and specifically visceral-fat research, the setting behind its approval. It is also the far larger molecule (44 residues against 16) and carries a mature, regulator-reviewed clinical dataset, whereas AOD-9604 holds US GRAS food-ingredient status but no medicinal approval.
Their short half-lives are the one place they converge — both clear on the order of well under an hour — but that similarity is superficial given how differently they act. Choosing between them in a protocol is really a choice of layer: model the fat cell directly, or model the upstream signal that feeds it.
The bottom line
AOD-9604 is the direct GH fragment — fat-focused, IGF-1-sparing, and best understood as lipolysis in isolation. Tesamorelin is the upstream GHRH analogue — it raises endogenous GH and IGF-1, carries an FDA-approved visceral-fat dataset, and models the whole axis rather than one cell type. Neither is a substitute for the other; they answer different research questions. For research-grade material, see our dedicated pages to buy AOD-9604 UK and buy Tesamorelin UK, each ≥99% purity with a COA.